ArticleFrontiers in pharmacology2025
Mechanisms of Lushi Runzao decoction in Treating Sjögren's syndrome by remodeling gut flora to regulate bile acid and short-chain fatty acid metabolism.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the mechanisms of Lushi Runzao decoction (LSRZT) in Treating Sjögren's Syndrome (SS) through gut flora, short-chain fatty acid (SCFAs) and metabolomics. Methods: Non Obese Diabetes (NOD) /LtJ mice were used as the model group, LSRZT and hydroxychloroquine (HCQ) were administered to the treatment group. Fecal samples were collected 4 weeks after the intervention. The microbiota, SCFAs and metabolites were analyzed using 16S ribosomal Ribonucleic Acid, Gas chromatography mass spectrometry analysis and Ultra High Performance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry. Results: LSRZT had obvious anti-inflammatory effect and can effectively improve the functional injury of submandibular gland; It improves the imbalance of gut microbiota and the related metabolic levels of SCFAs and bile acids, and regulates the levels of inflammatory factors and the contents of bile acids and caproic acid by regulating the abundance of Erysipelatoclostridiaceae, Gammaproteobacteria and Ruminococcaceae. Conclusion: LSRZT can reduce the level of inflammation and improve the imbalance of gut microbiota and metabolism. It provides a scientific basis for the clinical treatment of SS by LSRZT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.